---
title: "Breast Cancer Response Analysis – Group 12"
format:
  revealjs:
    smaller: true
    slide-number: true
    center: false
---

<!-- Embedded CSS for floating section label -->
<style>
.section-label {
  position: absolute;
  top: 10px;
  right: 20px;
  background: rgba(0,0,0,0.6);
  color: white;
  padding: 6px 12px;
  border-radius: 6px;
  font-size: 0.9rem;
  z-index: 9999;
}
</style>

---

## **Introduction**

<div class="section-label">Introduction</div>


### Group 12  
Sofie Emilie Hagelund • Henrique Gomes • Paula Meer Janssen •  
Shuyue Zhang • Eszter Hudra


### Objective  
Explore how **genotype**, **tumor characteristics**, and **treatments** relate to **treatment response** in breast cancer.

---

## Dataset Overview**

<div class="section-label">Materials and Methods</div>


- MAQC-II breast cancer dataset  


- Variables analyzed:
  - Demographics: Age, Race  
  - Clinical: Tumor size, Lymph nodes, Grade  
  - Biology: ER, PR, HER2  
  - Outcome: pCR (good) vs RD (bad)

---

## Demographics**

<div class="section-label">Materials and Methods</div>

![](presentation_files/04.png){fig-align="center"}

- Majority: white, age 40–59

---

## **Genotype Distribution**

<div class="section-label">Materials and Methods</div>

![](presentation_files/23.png){fig-align="center"}

- Frequent patterns: ER+, PR+, HER2– & triple negative  
- No visible age–genotype relationship

---

## **Genotype vs Treatment Response**

<div class="section-label">Analysis</div>

**Do expected prognoses match observed outcomes?**

![](presentation_files/18.png){fig-align="center"}

- ER+ = *worst* response  
- Triple negative & HER2+ only = *best* response  

---

## **Tumor Characteristics**

<div class="section-label">Analysis</div>

**Do size, grade, or lymph nodes predict response?**

![](presentation_files/19.png){fig-align="center"}

- ER+ poor response not explained by aggressiveness  
- ER-/PR- aggressive tumors still respond well  
- Size & lymph nodes show **no consistent correlation**

---

## **Treatment Types**

<div class="section-label">Analysis</div>

**Do specific genotypes benefit from specific treatments?**

<div class="section-label">Analysis</div>

![](presentation_files/22.png){fig-align="center"}

- Genotypes with **more specialized treatments** → better outcomes  
- TFAC/TFEC performs poorly for ER+ patients

---

## **Conclusion**

<div class="section-label">Discussion</div>

- **Genotype** predicts response better than size/grade  
- **Personalized treatment** improves outcomes  
- Classical prognoses (ER+) don’t always match real data  
- Supports **genotype-guided therapy strategies**

---

## **Thank you for your attention!**

We are happy to answer questions.
